150 related articles for article (PubMed ID: 34993132)
1. "How Long Have I Got?" in Stage IV NSCLC Patients With at Least 3 Months Up to 10 Years Survival, Accuracy of Long-, Intermediate-, and Short-Term Survival Prediction Is Not Good Enough to Answer This Question.
Guo H; Li H; Zhu L; Feng J; Huang X; Baak JPA
Front Oncol; 2021; 11():761042. PubMed ID: 34993132
[TBL] [Abstract][Full Text] [Related]
2. In stage IV pulmonary adenocarcinoma patients, treatment with Traditional Chinese Medicine alone gives prognostically superior results to treatment with Platinum-Based Chemotherapy alone.
Guo H; Li H; Zhu L; Huang X; Feng J; Baak JPA
Phytomedicine; 2023 Dec; 121():155087. PubMed ID: 37832267
[TBL] [Abstract][Full Text] [Related]
3. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
[TBL] [Abstract][Full Text] [Related]
4. Clinical and Biological Interpretation of Survival Curves of Cancer Patients, Exemplified With Stage IV Non-Small Cell Lung Cancers With Long Follow-up.
Baak JPA; Li H; Guo H
Front Oncol; 2022; 12():837419. PubMed ID: 35186767
[TBL] [Abstract][Full Text] [Related]
5. Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC.
Ying HQ; Liao YC; Luo YR; Xiong G; Huang Y; Nie RW; Xiong CF; Cheng XX
Pharmacol Res; 2021 Aug; 170():105734. PubMed ID: 34157424
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with the prognosis and long-term survival of patients with metastatic lung adenocarcinoma: a retrospective analysis.
Huang CY; Chen BH; Chou WC; Yang CT; Chang JW
J Thorac Dis; 2018 Apr; 10(4):2070-2078. PubMed ID: 29850110
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy with radiotherapy fails to improve prognosis of patients with stage IV non-small cell lung cancer: a retrospective cohort analysis of the THUNDER-2 study.
Liu L; Yuan M; Ding Z; Feng H; Zhang X; Liang N; Wang W; Wang J; Zhang Y; Zhou S; Kim AW; Castiglioni S; Suwinski R; Wang H; Hu P; Zhang J
Transl Lung Cancer Res; 2022 Dec; 11(12):2507-2520. PubMed ID: 36636420
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment Lung Immune Prognostic Index Is a Prognostic Marker of Chemotherapy and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
Minami S; Ihara S; Komuta K
World J Oncol; 2019 Feb; 10(1):35-45. PubMed ID: 30834050
[TBL] [Abstract][Full Text] [Related]
9. Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations.
Zheng L; Wang Y; Xu Z; Yang Q; Zhu G; Liao XY; Chen X; Zhu B; Duan Y; Sun J
Oncologist; 2019 Aug; 24(8):1031-e612. PubMed ID: 31040256
[TBL] [Abstract][Full Text] [Related]
10. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.
Dillman RO; Herndon J; Seagren SL; Eaton WL; Green MR
J Natl Cancer Inst; 1996 Sep; 88(17):1210-5. PubMed ID: 8780630
[TBL] [Abstract][Full Text] [Related]
11. Screening for patients with non-small cell lung cancer who could survive long term chemotherapy.
Wu XY; Huang XE
Asian Pac J Cancer Prev; 2015; 16(2):647-52. PubMed ID: 25684501
[TBL] [Abstract][Full Text] [Related]
12. CT-Based Radiomic Signature as a Prognostic Factor in Stage IV
Li H; Zhang R; Wang S; Fang M; Zhu Y; Hu Z; Dong D; Shi J; Tian J
Front Oncol; 2020; 10():57. PubMed ID: 32133282
[No Abstract] [Full Text] [Related]
13. Real world utilization of EGFR TKIs and prognostic factors for survival in NSCLC during 2010-2016 in Sweden: A nationwide observational study.
Bergqvist M; Christensen HN; Wiklund F; Bergström S
Int J Cancer; 2020 May; 146(9):2510-2517. PubMed ID: 31350754
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
Fan Y; Huang ZY; Yu HF; Luo LH
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
[TBL] [Abstract][Full Text] [Related]
16. A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands.
Ten Berge DMHJ; Aarts MJ; Groen HJM; Aerts JGJV; Kloover JS
Eur J Cancer; 2022 Apr; 165():195-204. PubMed ID: 35248841
[TBL] [Abstract][Full Text] [Related]
17. Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.
Schuette W; Schirmacher P; Eberhardt WEE; Dietel M; Zirrgiebel U; Muehlenhoff L; Thomas M
BMC Cancer; 2018 Feb; 18(1):135. PubMed ID: 29402243
[TBL] [Abstract][Full Text] [Related]
18. A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy.
Song J; Shi J; Dong D; Fang M; Zhong W; Wang K; Wu N; Huang Y; Liu Z; Cheng Y; Gan Y; Zhou Y; Zhou P; Chen B; Liang C; Liu Z; Li W; Tian J
Clin Cancer Res; 2018 Aug; 24(15):3583-3592. PubMed ID: 29563137
[No Abstract] [Full Text] [Related]
19. Long-term outcomes of high-dose (74 GyE) proton beam therapy with concurrent chemotherapy for stage III nonsmall-cell lung cancer.
Ohnishi K; Ishikawa H; Nakazawa K; Shiozawa T; Mori Y; Nakamura M; Okumura T; Sekine I; Hizawa N; Sakurai H
Thorac Cancer; 2021 May; 12(9):1320-1327. PubMed ID: 33675285
[TBL] [Abstract][Full Text] [Related]
20. Long-term survival of stage IV melanoma patients: evaluation on 640 melanoma patients entering stage IV between 2014 and 2017.
Reitmajer M; Leiter U; Nanz L; Amaral T; Flatz L; Garbe C; Forschner A
J Cancer Res Clin Oncol; 2024 Jan; 150(1):15. PubMed ID: 38238578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
